Yioti Georgia G, Panagiotou Orestis A, Vartholomatos Georgios A, Kolaitis Nikolaos I, Pappa Chrisavgi N, Evangelou Evangelos, Stefaniotou Maria I
Department of Ophthalmology, University of Ioannina School of Medicine, Ioannina, Greece.
Ophthalmic Genet. 2013 Sep;34(3):130-9. doi: 10.3109/13816810.2012.746376. Epub 2013 Jan 4.
The genetic background of retinal vein occlusion (RVO) remains unclear. In the current study, we aimed to replicate polymorphisms related to thrombophilia/hypofibrinolysis in a Greek population and also systematically summarize current evidence available on the topic.
A total of 48 RVO patients and 53 controls were genotyped for factor V H1299R and V Leiden, β-fibrinogen G455A, PAI-1 4G/5G, ACE I/D, HPA1, prothrombin G20210A, factor XIII Val34Leu, MTHFR A1298C and C677T polymorphisms. We examined the association between RVO and the above polymorphisms under a per-allele genetic model in a Greek unrelated case/control population. Additionally, searching PubMed up to January 2012, we identified existing evidence on these polymorphisms and performed meta-analyses.
A total of three polymorphisms had nominally significant associations with RVO. These associations pertained to ACE D allele (odds ratio, OR, 2.08 [95% CI, 1.12-3.85], p = 0.02); factor XIII 34Leu allele (OR = 0.41 [95% CI, 0.18-0.95], p = 0.037] and MTHFR 677T variant (OR = 2.20 [95% CI 1.10-4.40], p = 0.026). We performed a meta-analysis on the associations between RVO and PAI-1 (n = 5), factor V Leiden (n = 21), MTHFR C677T (n = 19) and prothrombin G20210A (n = 21). We observed nominally significant associations only for PAI-1 (OR = 1.27 [95% CI, 1.02-1.60, p = 0.036]) (I(2) = 44.7%), and factor V Leiden (OR = 1.40 [95% CI, 1.07-1.84, p = 0.015]) (I(2) = 3.6%) using random effects model.
Our results suggest that there may be an association between increased risk for RVO and ACE I/D, MTHFR C677T, PAI-1 4G/5G and factor V Leiden polymorphisms, whereas the Val34Leu variant may exert a protective effect.
视网膜静脉阻塞(RVO)的遗传背景尚不清楚。在本研究中,我们旨在在希腊人群中复制与血栓形成倾向/纤维蛋白溶解功能低下相关的多态性,并系统总结该主题的现有证据。
对48例RVO患者和53例对照进行了因子V H1299R和V Leiden、β-纤维蛋白原G455A、PAI-1 4G/5G、ACE I/D、HPA1、凝血酶原G20210A、因子XIII Val34Leu、MTHFR A1298C和C677T多态性的基因分型。我们在希腊无关病例/对照人群中,在每个等位基因遗传模型下检查了RVO与上述多态性之间的关联。此外,检索截至2012年1月的PubMed,我们确定了关于这些多态性的现有证据并进行了荟萃分析。
共有三种多态性与RVO存在名义上的显著关联。这些关联涉及ACE D等位基因(比值比,OR,2.08 [95%可信区间,1.12 - 3.85],p = 0.02);因子XIII 34Leu等位基因(OR = 0.41 [95%可信区间,0.18 - 0.95],p = 0.037)和MTHFR 677T变异体(OR = 2.20 [95%可信区间1.10 - 4.40],p = 0.026)。我们对RVO与PAI-1(n = 5)、因子V Leiden(n = 21)、MTHFR C677T(n = 19)和凝血酶原G20210A(n = 21)之间的关联进行了荟萃分析。使用随机效应模型,我们仅观察到PAI-1(OR = 1.27 [95%可信区间,1.02 - 1.60,p = 0.036])(I² = 44.7%)和因子V Leiden(OR = 1.40 [95%可信区间,1.07 - 1.84,p = 0.015])(I² = 3.6%)存在名义上的显著关联。
我们的数据表明,RVO风险增加可能与ACE I/D、MTHFR C677T、PAI-1 4G/5G和因子V Leiden多态性之间存在关联,而Val34Leu变异体可能具有保护作用。